Literature DB >> 24184504

ABCC4 is regulated by microRNA-124a and microRNA-506.

Svetlana M Markova1, Deanna L Kroetz2.   

Abstract

Multidrug resistance protein 4 (MRP4, ABCC4) is an efflux membrane transporter expressed in renal tubules, hepatocytes, brain capillaries, prostate and blood cells. MRP4 drives energy dependent efflux of important physiological and pharmacological compounds. MRP4 expression and function is highly variable but cannot be fully attributed to known mechanisms. The goal of this study was to characterize ABCC4 regulation by miRNAs and to assess the influence of ABCC4 3'-UTR polymorphisms on ABCC4 regulation by miRNAs. miR-124a and miR-506 decreased MRP4 protein levels in HEK293T/17 cells 20-30% and MRP4 function by 50%. These miRNAs did not affect ABCC4 mRNA expression. Moreover, miR-124a and miR-506 expression was negatively correlated with MRP4 protein expression in 26 human kidney samples (Spearman r=-0.62, P=0.007 and r=-0.41, P=0.03 for miR-124a and miR-506, respectively). To assess the effect of ABCC4 3'-UTR polymorphisms, six common 3'-UTR haplotypes were inferred in Caucasians, African Americans and Asians and tested in luciferase reporter assays. Multiple ABCC4 3'-UTR haplotypes caused significant reductions in luciferase activity; in the presence of miR-124a or miR-506 mimics the luciferase activity of all six ABCC4 3'-UTR haplotypes was further reduced. Mutation of the putative binding site for miR-124a and miR-506 in the ABCC4 3'-UTR eliminated the effect of these miRNAs. In conclusion, ABCC4 is directly regulated by miR-124a and miR-506 but polymorphisms in the ABCC4 3'-UTR have no significant effect on this miRNA regulation. Regulation of ABCC4 by miRNAs represents a novel mechanism for regulation of MRP4 function.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (ATP-binding cassette transporter member C4); (monochlorobimane); (multidrug resistance protein member 4); ABCC4; MCB; MRP4; Multidrug resistance associated protein; Polymorphism.; microRNA

Mesh:

Substances:

Year:  2013        PMID: 24184504      PMCID: PMC3927324          DOI: 10.1016/j.bcp.2013.10.017

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  49 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans.

Authors:  R F Ketting; S E Fischer; E Bernstein; T Sijen; G J Hannon; R H Plasterk
Journal:  Genes Dev       Date:  2001-10-15       Impact factor: 11.361

3.  The role of miR-506 in transformed 16HBE cells induced by anti-benzo[a]pyrene-trans-7,8-dihydrodiol-9,10-epoxide.

Authors:  Yao Zhao; Huanying Liu; Yuanqi Li; Jianjun Wu; Anne R Greenlee; Chengfeng Yang; Yiguo Jiang
Journal:  Toxicol Lett       Date:  2011-06-24       Impact factor: 4.372

4.  The ABCC4 gene is a promising target for pancreatic cancer therapy.

Authors:  Zhuo Zhang; Jiancheng Wang; Baiyong Shen; Chenghong Peng; Minhua Zheng
Journal:  Gene       Date:  2011-10-02       Impact factor: 3.688

5.  A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth.

Authors:  K L Streicher; W Zhu; K P Lehmann; R W Georgantas; C A Morehouse; P Brohawn; R A Carrasco; Z Xiao; D A Tice; B W Higgs; L Richman; B Jallal; K Ranade; Y Yao
Journal:  Oncogene       Date:  2011-08-22       Impact factor: 9.867

Review 6.  Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy.

Authors:  Dietrich Keppler
Journal:  Handb Exp Pharmacol       Date:  2011

7.  Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia.

Authors:  Marc Ansari; Géraldine Sauty; Malgorzata Labuda; Vincent Gagné; Caroline Laverdière; Albert Moghrabi; Daniel Sinnett; Maja Krajinovic
Journal:  Blood       Date:  2009-06-10       Impact factor: 22.113

Review 8.  Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules.

Authors:  Frans G M Russel; Jan B Koenderink; Rosalinde Masereeuw
Journal:  Trends Pharmacol Sci       Date:  2008-03-18       Impact factor: 14.819

9.  The nuclear RNase III Drosha initiates microRNA processing.

Authors:  Yoontae Lee; Chiyoung Ahn; Jinju Han; Hyounjeong Choi; Jaekwang Kim; Jeongbin Yim; Junho Lee; Patrick Provost; Olof Rådmark; Sunyoung Kim; V Narry Kim
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

10.  Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.

Authors:  Gunter Meister; Markus Landthaler; Agnieszka Patkaniowska; Yair Dorsett; Grace Teng; Thomas Tuschl
Journal:  Mol Cell       Date:  2004-07-23       Impact factor: 17.970

View more
  20 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

2.  Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity.

Authors:  Mei-Mei Li; Balasubrahmanyam Addepalli; Mei-Juan Tu; Qiu-Xia Chen; Wei-Peng Wang; Patrick A Limbach; Janine M LaSalle; Su Zeng; Min Huang; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2015-05-01       Impact factor: 3.922

Review 3.  The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs.

Authors:  Y He; J R Chevillet; G Liu; T K Kim; K Wang
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

4.  Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy.

Authors:  Pui Yan Ho; Zhijian Duan; Neelu Batra; Joseph L Jilek; Mei-Juan Tu; Jing-Xin Qiu; Zihua Hu; Theodore Wun; Primo N Lara; Ralph W DeVere White; Hong-Wu Chen; Ai-Ming Yu
Journal:  J Pharmacol Exp Ther       Date:  2018-03-30       Impact factor: 4.030

5.  MiR-506 suppresses proliferation of hepatoma cells through targeting YAP mRNA 3'UTR.

Authors:  Yue Wang; Ming Cui; Bao-di Sun; Fa-bao Liu; Xiao-dong Zhang; Li-hong Ye
Journal:  Acta Pharmacol Sin       Date:  2014-08-04       Impact factor: 6.150

Review 6.  MicroRNAs and drug resistance in prostate cancers.

Authors:  Feng Li; Ram I Mahato
Journal:  Mol Pharm       Date:  2014-04-29       Impact factor: 4.939

7.  MiR-506 inhibits PRRSV replication in MARC-145 cells via CD151.

Authors:  Junjing Wu; Xianwen Peng; Ao Zhou; Mu Qiao; Huayu Wu; Hongwei Xiao; Guisheng Liu; Xinmin Zheng; Shujun Zhang; Shuqi Mei
Journal:  Mol Cell Biochem       Date:  2014-05-31       Impact factor: 3.396

8.  Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells.

Authors:  Mei-Mei Li; Wei-Peng Wang; Wen-Juan Wu; Min Huang; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2014-08-26       Impact factor: 3.922

9.  microRNA-506 regulates proliferation, migration and invasion in hepatocellular carcinoma by targeting F-spondin 1 (SPON1).

Authors:  Wei Dai; Hai-Li Huang; Min Hu; Si-Jie Wang; Hui-Juan He; Nian-Pin Chen; Ming-Yi Li
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

Review 10.  microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment.

Authors:  Igor Koturbash; William H Tolleson; Lei Guo; Dianke Yu; Si Chen; Huixiao Hong; William Mattes; Baitang Ning
Journal:  Biomark Med       Date:  2015-10-26       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.